Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance
Open Access
- 2 December 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0260852
Abstract
Establishing a universally applicable protocol to assess the impact of BRCA1 variants of uncertain significance (VUS) expression is a problem which has yet to be resolved despite major progresses have been made. The numerous difficulties which must be overcome include the choices of cellular models and functional assays. We hypothesised that the use of induced pluripotent stem (iPS) cells might facilitate the standardisation of protocols for classification, and could better model the disease process. We generated eight iPS cell lines from patient samples expressing either BRCA1 pathogenic variants, non-pathogenic variants, or BRCA1 VUSs. The impact of these variants on DNA damage repair was examined using a ɣH2AX foci formation assay, a Homologous Repair (HR) reporter assay, and a chromosome abnormality assay. Finally, all lines were tested for their ability to differentiate into mammary lineages in vitro. While the results obtained from the two BRCA1 pathogenic variants were consistent with published data, some other variants exhibited differences. The most striking of these was the BRCA1 variant Y856H (classified as benign), which was unexpectedly found to present a faulty HR repair pathway, a finding linked to the presence of an additional variant in the ATM gene. Finally, all lines were able to differentiate first into mammospheres, and then into more advanced mammary lineages expressing luminal- or basal-specific markers. This study stresses that BRCA1 genetic analysis alone is insufficient to establish a reliable and functional classification for assessment of clinical risk, and that it cannot be performed without considering the other genetic aberrations which may be present in patients. The study also provides promising opportunities for elucidating the physiopathology and clinical evolution of breast cancer, by using iPS cells.Keywords
Funding Information
- The European Union Scholarship Programme
- Breast Cancer Now (2015NovPR609)
- Blood Cancer UK (13043; previously called Bloodwise)
- King's College London
This publication has 68 references indexed in Scilit:
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingGenome Research, 2012
- Multispectral imaging flow cytometry reveals distinct frequencies of γ‐H2AX foci induction in DNA double strand break repair defective human cell linesCytometry Part A, 2011
- Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell FateCell Stem Cell, 2011
- DNA damage signaling in response to double-strand breaks during mitosisJournal of Cell Biology, 2010
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation CarriersCancer Research, 2009
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriersBritish Journal of Cancer, 2007
- Involvement of novel autophosphorylation sites in ATM activationThe EMBO Journal, 2006